Picture loading failed.

Pre-Made Letolizumab biosimilar, Single Domain Variable Fragment;H, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Letolizumab (INN; development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-307-1mg 1mg Inquiry
GMP-Bios-ab-307-10mg 10mg Inquiry
GMP-Bios-ab-307-100mg 100mg Inquiry
GMP-Bios-ab-307-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Letolizumab biosimilar, Single Domain Variable Fragment;H, Anti-CD40LG Antibody: Anti-IGM/IMD3/TRAP/gp39/CD154/CD40L/HIGM1/T-BAM/TNFSF5/hCD40L therapeutic antibody
INN Name Letolizumab
TargetCD40LG
FormatSingle Domain Variable Fragment;H
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCna
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesBristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute
Conditions Approvedna
Conditions ActiveGraft-versus-host disease;Idiopathic thrombocytopenic purpura
Conditions Discontinuedna
Development Techna